Immunome Inc Net Assets
Immunome Inc net assets. Based on the latest financial reports, Immunome Inc (IMNM) has net assets worth $525.08 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($565.38 Million) and total liabilities ($40.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Immunome Inc (IMNM) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $525.08 Million |
| % of Total Assets | 92.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1216.47% |
| 10-Year Change | N/A |
| Growth Volatility | 245.7 |
Net Assets of Immunome Inc (2018–2025)
Net assets of Immunome Inc from 2018 to 2025. This chart illustrates how Immunome Inc's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of Immunome Inc to track the company's year-over-year net asset growth rate.
Annual Net Assets for Immunome Inc (2018–2025)
The table below shows the annual net assets of Immunome Inc from 2018 to 2025. For live market cap and overall valuation, see IMNM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $634.34 Million | +250.15% |
| 2024-12-31 | $181.16 Million | +51.12% |
| 2023-12-31 | $119.88 Million | +619.88% |
| 2022-12-31 | $16.65 Million | -65.44% |
| 2021-12-31 | $48.19 Million | +16.54% |
| 2020-12-31 | $41.34 Million | +216.04% |
| 2019-12-31 | $-35.63 Million | -41.36% |
| 2018-12-31 | $-25.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunome Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70205100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Immunome Inc Net Assets Breakdown (December 2025)
Immunome Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Components | $1.36 Billion | 214.79% |
| Total Equity | $634.34 Million | 100.00% |
Immunome Inc Competitors by Market Cap
The table below lists competitors of Immunome Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
$2.15 Billion |
|
Electric Connector Technology Co Ltd
SHE:300679
|
$2.15 Billion |
|
Foran Energy Group Co Ltd
SHE:002911
|
$2.15 Billion |
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
$2.15 Billion |
|
LTC Properties Inc
NYSE:LTC
|
$2.15 Billion |
|
Enterprise Financial Services
NASDAQ:EFSC
|
$2.15 Billion |
|
Tiger Brands Ltd
JSE:TBS
|
$2.15 Billion |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
$2.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunome Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 181,165,000 to 634,343,000, a change of 453,178,000 (250.1%).
- Net loss of 212,394,000 reduced equity.
- New share issuances of 678,900,000 increased equity.
- Other comprehensive income decreased equity by 57,000.
- Other factors decreased equity by 13,271,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-212.39 Million | -33.48% |
| Share Issuances | $678.90 Million | +107.02% |
| Other Comprehensive Income | $-57.00K | -0.01% |
| Other Changes | $-13.27 Million | -2.09% |
| Total Change | $- | 250.15% |
Book Value vs Market Value Analysis
This analysis compares Immunome Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-23.07 | $18.21 | x |
| 2019-12-31 | $-6.20 | $18.21 | x |
| 2020-12-31 | $4.09 | $18.21 | x |
| 2021-12-31 | $4.18 | $18.21 | x |
| 2022-12-31 | $1.37 | $18.21 | x |
| 2023-12-31 | $6.04 | $18.21 | x |
| 2024-12-31 | $3.09 | $18.21 | x |
| 2025-12-31 | $7.26 | $18.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunome Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3059.99%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.08x
- Recent ROE (-33.48%) is above the historical average (-74.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.32 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.99 Million |
| 2020 | -41.41% | 0.00% | 0.00x | 1.08x | $-21.25 Million |
| 2021 | -51.28% | 0.00% | 0.00x | 1.20x | $-29.53 Million |
| 2022 | -221.56% | -556.75% | 0.28x | 1.44x | $-38.56 Million |
| 2023 | -89.09% | -761.92% | 0.09x | 1.24x | $-118.79 Million |
| 2024 | -161.71% | -3240.38% | 0.04x | 1.33x | $-311.08 Million |
| 2025 | -33.48% | -3059.99% | 0.01x | 1.08x | $-275.83 Million |
Industry Comparison
This section compares Immunome Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunome Inc (IMNM) | $525.08 Million | 0.00% | 0.08x | $2.15 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more